The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: Between lights and shadows

Maria Di Vita, Alessandro Cappellani, Gaetano Piccolo, Antonio Zanghì, Andrea Cavallaro, Giulio Bertola, Antonio Bolognese, Gaetano Facchini, Carmine D'Aniello, Raffaele Di Francia, Francesco Cardì, Massimiliano Berretta

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gastric cancer is one of the most dreadful neoplastic diseases and remains the second cause of cancer death worldwide. Patients who develop peritoneal metastasis have a poor prognosis, with a median survival of less than 6 months. Despite being the cause of 60% of deaths from gastric cancer, peritoneal metastasis can still be considered a local disease and a local multidisciplinary approach can improve the prognosis even in this end-stage disease. At present, hyperthermic intraperitoneal chemotherapy (HIPEC) is the most widely accepted treatment for peritoneal surface diseases and can be performed in patients with different stages of cancer and with various antitumoral drugs. We performed a systematic review of the current status of HIPEC in the treatment of gastric peritoneal metastasis in an attempt to obtain answers to the questions that still remain: do results differ with these different methods? Does HIPEC exert a significant effect on the intracavitary delivery of drugs? Which patients should be treated and which should not? What can we expect from this approach in terms of survival, morbidity, and mortality? On reviewing the literature, despite the lack of trials comparing the different methods, we found that HIPEC has been shown to be an effective tool whenever a complete or an almost complete resection of the peritoneal implants can be performed. Therefore, it is advisable to refer all at-risk patients to specialized centers to be enrolled in randomized trials to achieve truly reliable results.

Original languageEnglish
Pages (from-to)123-138
Number of pages16
JournalAnti-Cancer Drugs
Volume26
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Stomach Neoplasms
Carcinoma
Light
Drug Therapy
Neoplasm Metastasis
Cause of Death
Peritoneal Diseases
Survival
Second Primary Neoplasms
Therapeutics
Pharmaceutical Preparations
Stomach
Morbidity
Mortality
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer : Between lights and shadows. / Di Vita, Maria; Cappellani, Alessandro; Piccolo, Gaetano; Zanghì, Antonio; Cavallaro, Andrea; Bertola, Giulio; Bolognese, Antonio; Facchini, Gaetano; D'Aniello, Carmine; Di Francia, Raffaele; Cardì, Francesco; Berretta, Massimiliano.

In: Anti-Cancer Drugs, Vol. 26, No. 2, 2015, p. 123-138.

Research output: Contribution to journalArticle

Di Vita, Maria ; Cappellani, Alessandro ; Piccolo, Gaetano ; Zanghì, Antonio ; Cavallaro, Andrea ; Bertola, Giulio ; Bolognese, Antonio ; Facchini, Gaetano ; D'Aniello, Carmine ; Di Francia, Raffaele ; Cardì, Francesco ; Berretta, Massimiliano. / The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer : Between lights and shadows. In: Anti-Cancer Drugs. 2015 ; Vol. 26, No. 2. pp. 123-138.
@article{be2ae4c9a9dc4b02803f21b8b40ce271,
title = "The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: Between lights and shadows",
abstract = "Gastric cancer is one of the most dreadful neoplastic diseases and remains the second cause of cancer death worldwide. Patients who develop peritoneal metastasis have a poor prognosis, with a median survival of less than 6 months. Despite being the cause of 60{\%} of deaths from gastric cancer, peritoneal metastasis can still be considered a local disease and a local multidisciplinary approach can improve the prognosis even in this end-stage disease. At present, hyperthermic intraperitoneal chemotherapy (HIPEC) is the most widely accepted treatment for peritoneal surface diseases and can be performed in patients with different stages of cancer and with various antitumoral drugs. We performed a systematic review of the current status of HIPEC in the treatment of gastric peritoneal metastasis in an attempt to obtain answers to the questions that still remain: do results differ with these different methods? Does HIPEC exert a significant effect on the intracavitary delivery of drugs? Which patients should be treated and which should not? What can we expect from this approach in terms of survival, morbidity, and mortality? On reviewing the literature, despite the lack of trials comparing the different methods, we found that HIPEC has been shown to be an effective tool whenever a complete or an almost complete resection of the peritoneal implants can be performed. Therefore, it is advisable to refer all at-risk patients to specialized centers to be enrolled in randomized trials to achieve truly reliable results.",
author = "{Di Vita}, Maria and Alessandro Cappellani and Gaetano Piccolo and Antonio Zangh{\`i} and Andrea Cavallaro and Giulio Bertola and Antonio Bolognese and Gaetano Facchini and Carmine D'Aniello and {Di Francia}, Raffaele and Francesco Card{\`i} and Massimiliano Berretta",
year = "2015",
doi = "10.1097/CAD.0000000000000179",
language = "English",
volume = "26",
pages = "123--138",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer

T2 - Between lights and shadows

AU - Di Vita, Maria

AU - Cappellani, Alessandro

AU - Piccolo, Gaetano

AU - Zanghì, Antonio

AU - Cavallaro, Andrea

AU - Bertola, Giulio

AU - Bolognese, Antonio

AU - Facchini, Gaetano

AU - D'Aniello, Carmine

AU - Di Francia, Raffaele

AU - Cardì, Francesco

AU - Berretta, Massimiliano

PY - 2015

Y1 - 2015

N2 - Gastric cancer is one of the most dreadful neoplastic diseases and remains the second cause of cancer death worldwide. Patients who develop peritoneal metastasis have a poor prognosis, with a median survival of less than 6 months. Despite being the cause of 60% of deaths from gastric cancer, peritoneal metastasis can still be considered a local disease and a local multidisciplinary approach can improve the prognosis even in this end-stage disease. At present, hyperthermic intraperitoneal chemotherapy (HIPEC) is the most widely accepted treatment for peritoneal surface diseases and can be performed in patients with different stages of cancer and with various antitumoral drugs. We performed a systematic review of the current status of HIPEC in the treatment of gastric peritoneal metastasis in an attempt to obtain answers to the questions that still remain: do results differ with these different methods? Does HIPEC exert a significant effect on the intracavitary delivery of drugs? Which patients should be treated and which should not? What can we expect from this approach in terms of survival, morbidity, and mortality? On reviewing the literature, despite the lack of trials comparing the different methods, we found that HIPEC has been shown to be an effective tool whenever a complete or an almost complete resection of the peritoneal implants can be performed. Therefore, it is advisable to refer all at-risk patients to specialized centers to be enrolled in randomized trials to achieve truly reliable results.

AB - Gastric cancer is one of the most dreadful neoplastic diseases and remains the second cause of cancer death worldwide. Patients who develop peritoneal metastasis have a poor prognosis, with a median survival of less than 6 months. Despite being the cause of 60% of deaths from gastric cancer, peritoneal metastasis can still be considered a local disease and a local multidisciplinary approach can improve the prognosis even in this end-stage disease. At present, hyperthermic intraperitoneal chemotherapy (HIPEC) is the most widely accepted treatment for peritoneal surface diseases and can be performed in patients with different stages of cancer and with various antitumoral drugs. We performed a systematic review of the current status of HIPEC in the treatment of gastric peritoneal metastasis in an attempt to obtain answers to the questions that still remain: do results differ with these different methods? Does HIPEC exert a significant effect on the intracavitary delivery of drugs? Which patients should be treated and which should not? What can we expect from this approach in terms of survival, morbidity, and mortality? On reviewing the literature, despite the lack of trials comparing the different methods, we found that HIPEC has been shown to be an effective tool whenever a complete or an almost complete resection of the peritoneal implants can be performed. Therefore, it is advisable to refer all at-risk patients to specialized centers to be enrolled in randomized trials to achieve truly reliable results.

UR - http://www.scopus.com/inward/record.url?scp=84940562307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940562307&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000179

DO - 10.1097/CAD.0000000000000179

M3 - Article

C2 - 25406023

AN - SCOPUS:84940562307

VL - 26

SP - 123

EP - 138

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -